CD38: From Positive to Negative Expression after Daratumumab Treatment

Bonell Patiño-Escobar1, Roberto Ramos1, Maximo Linares1

  • 1Hematology, Instituto Nacional de Cancerología, Bogota, COL.

Cureus
|May 14, 2020
PubMed
Summary

Daratumumab treatment for multiple myeloma can lead to CD38 expression negativization in plasma cells. This case study shows a patient developing this resistance mechanism after four treatment cycles.

Related Concept Videos